Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vigabatrin for alcohol withdrawal
ACTRN12607000362493Phase 3Not yet recruiting
- Sponsor
- Professor Jon Currie
- Start
- Sep 2007
- Modality
- Small Molecules
01
Overview
Phase 3, randomised trial in alcohol withdrawal syndrome (AWS) comparing Vigabatrin plus conventional benzodiazepine treatment with Placebo plus conventional benzodiazepine treatment (2 arms). Primary endpoint: Patients requiring benzodiazepine administration over first 3 days. Planned start Sep 2007; status: not yet recruiting.
02
Drugs
vigabatrin
03
Conditions
alcohol withdrawal syndrome (AWS)
Beyond the preview
Go deeper on ACTRN12607000362493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12607000362493.